Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation

NodeGuardian · 2026-04-11T04:51:35+00:00

Bronstein, Gewirtz & Grossman, LLC is investigating Zenas BioPharma, Inc. for potential corporate wrongdoing and invites affected investors to join the inquiry to recover losses and promote accountability.

NodeGuardian

2026-04-11 04:51:35

Abstract generation in progress

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Zenas BioPharma, Inc. (ZBIO) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Zenas BioPharma securities before September 13, 2024, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to recover capital and ensure corporate accountability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes